Skip to main content
HairCited

[Androgenetic alopecia: where do we stand in 2024?].

Federica Bertone, Sadaf Sanii, Sébastien Menzinger, David Alvarez Martinez, Yassaman Alipour Tehrany-Götti
Review Revue medicale suisse 2024 2 Zitierungen
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D38563540'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Studientyp
Review
Intervention
[Androgenetic alopecia: where do we stand in 2024?]. None
Vergleichsgruppe
Placebo
Wirkungsrichtung
Mixed
Verzerrungsrisiko
Unclear

Abstract

Androgenetic alopecia, the most prevalent type of hair loss, is characterized by a receding hairline in men and diffuse thinning of hair in women. Despite being considered a benign condition, it can exert a considerable psychological toll, especially on women and young men. Despite its high prevalence, only a limited number of medications have received approval for its treatment. In this article, we review the available treatment options, assessing their efficacy and potential side effects. Additionally, we explore minimally-invasive strategies such as photobiomodulation, micro-needling and platelet-rich plasma therapy. Furthermore, we delve into discussions on hair transplantation and camouflage methods.

Used In Evidence Reviews

Similar Papers